These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 8547652)
1. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Tsujimura T; Morimoto M; Hashimoto K; Moriyama Y; Kitayama H; Matsuzawa Y; Kitamura Y; Kanakura Y Blood; 1996 Jan; 87(1):273-83. PubMed ID: 8547652 [TBL] [Abstract][Full Text] [Related]
2. Mechanisms of constitutive activation of c-kit receptor tyrosine kinase. Tsujimura T; Kanakura Y; Kitamura Y Leukemia; 1997 Apr; 11 Suppl 3():396-8. PubMed ID: 9209403 [TBL] [Abstract][Full Text] [Related]
3. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Tsujimura T; Furitsu T; Morimoto M; Kanayama Y; Nomura S; Matsuzawa Y; Kitamura Y; Kanakura Y Int Arch Allergy Immunol; 1995 Apr; 106(4):377-85. PubMed ID: 7536501 [TBL] [Abstract][Full Text] [Related]
4. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885 [TBL] [Abstract][Full Text] [Related]
5. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Piao X; Bernstein A Blood; 1996 Apr; 87(8):3117-23. PubMed ID: 8605325 [TBL] [Abstract][Full Text] [Related]
6. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Tsujimura T; Furitsu T; Morimoto M; Isozaki K; Nomura S; Matsuzawa Y; Kitamura Y; Kanakura Y Blood; 1994 May; 83(9):2619-26. PubMed ID: 7513208 [TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Shivakrupa R; Bernstein A; Watring N; Linnekin D Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613 [TBL] [Abstract][Full Text] [Related]
9. Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice. Tsujimura T; Morii E; Nozaki M; Hashimoto K; Moriyama Y; Takebayashi K; Kondo T; Kanakura Y; Kitamura Y Blood; 1996 Aug; 88(4):1225-33. PubMed ID: 8695840 [TBL] [Abstract][Full Text] [Related]
10. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Beghini A; Cairoli R; Morra E; Larizza L Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703 [TBL] [Abstract][Full Text] [Related]
11. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. Ma Y; Longley BJ; Wang X; Blount JL; Langley K; Caughey GH J Invest Dermatol; 1999 Feb; 112(2):165-70. PubMed ID: 9989791 [TBL] [Abstract][Full Text] [Related]
12. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance. Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282 [TBL] [Abstract][Full Text] [Related]
13. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. London CA; Galli SJ; Yuuki T; Hu ZQ; Helfand SC; Geissler EN Exp Hematol; 1999 Apr; 27(4):689-97. PubMed ID: 10210327 [TBL] [Abstract][Full Text] [Related]
14. Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase. Moriyama Y; Tsujimura T; Hashimoto K; Morimoto M; Kitayama H; Matsuzawa ; Kitamura Y; Kanakura Y J Biol Chem; 1996 Feb; 271(7):3347-50. PubMed ID: 8631931 [TBL] [Abstract][Full Text] [Related]
15. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Hashimoto K; Tsujimura T; Moriyama Y; Yamatodani A; Kimura M; Tohya K; Morimoto M; Kitayama H; Kanakura Y; Kitamura Y Am J Pathol; 1996 Jan; 148(1):189-200. PubMed ID: 8546206 [TBL] [Abstract][Full Text] [Related]
16. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. Boissan M; Feger F; Guillosson JJ; Arock M J Leukoc Biol; 2000 Feb; 67(2):135-48. PubMed ID: 10670573 [TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. Ueda S; Ikeda H; Mizuki M; Ishiko J; Matsumura I; Tanaka H; Shibayama H; Sugahara H; Takai E; Zhang X; Machii T; Kanakura Y Int J Hematol; 2002 Dec; 76(5):427-35. PubMed ID: 12512837 [TBL] [Abstract][Full Text] [Related]
18. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Nakahara M; Isozaki K; Hirota S; Miyagawa J; Hase-Sawada N; Taniguchi M; Nishida T; Kanayama S; Kitamura Y; Shinomura Y; Matsuzawa Y Gastroenterology; 1998 Nov; 115(5):1090-5. PubMed ID: 9797363 [TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Chian R; Young S; Danilkovitch-Miagkova A; Rönnstrand L; Leonard E; Ferrao P; Ashman L; Linnekin D Blood; 2001 Sep; 98(5):1365-73. PubMed ID: 11520784 [TBL] [Abstract][Full Text] [Related]
20. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Sundström M; Vliagoftis H; Karlberg P; Butterfield JH; Nilsson K; Metcalfe DD; Nilsson G Immunology; 2003 Jan; 108(1):89-97. PubMed ID: 12519307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]